WilmerHale Counsels Exonics Therapeutics in $5M Seed Financing

WilmerHale Counsels Exonics Therapeutics in $5M Seed Financing

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Helping clients launch their businesses and transform their innovative ideas into successful companies.

Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, announced a commitment of $5 million in seed financing from CureDuchenne Ventures. The initial seed funding will allow Exonics to advance the preclinical research of its Scientific Founder and Chief Science Advisor Eric Olson, PhD.

The WilmerHale team representing Exonics Therapeutics was led by Gary Schall.

Read Exonics Therapeutics' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel